Carisma Therapeutics (CARM) Competitors $0.22 +0.02 (+11.44%) As of 12:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CARM vs. NRXP, SRZN, ATHE, CVKD, PLUR, MRNS, KZR, ALXO, ESLA, and ALLKShould you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include NRx Pharmaceuticals (NRXP), Surrozen (SRZN), Alterity Therapeutics (ATHE), Cadrenal Therapeutics (CVKD), Pluri (PLUR), Marinus Pharmaceuticals (MRNS), Kezar Life Sciences (KZR), ALX Oncology (ALXO), Estrella Immunopharma (ESLA), and Allakos (ALLK). These companies are all part of the "pharmaceutical products" industry. Carisma Therapeutics vs. NRx Pharmaceuticals Surrozen Alterity Therapeutics Cadrenal Therapeutics Pluri Marinus Pharmaceuticals Kezar Life Sciences ALX Oncology Estrella Immunopharma Allakos Carisma Therapeutics (NASDAQ:CARM) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk, institutional ownership and community ranking. Do institutionals & insiders hold more shares of CARM or NRXP? 44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 12.6% of Carisma Therapeutics shares are held by insiders. Comparatively, 19.0% of NRx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is CARM or NRXP more profitable? NRx Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -314.78%. NRx Pharmaceuticals' return on equity of 0.00% beat Carisma Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-314.78% -957.20% -96.39% NRx Pharmaceuticals N/A N/A -449.16% Do analysts rate CARM or NRXP? Carisma Therapeutics presently has a consensus price target of $1.93, indicating a potential upside of 853.44%. NRx Pharmaceuticals has a consensus price target of $28.50, indicating a potential upside of 1,270.19%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Carisma Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43NRx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has more risk and volatility, CARM or NRXP? Carisma Therapeutics has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Does the MarketBeat Community believe in CARM or NRXP? NRx Pharmaceuticals received 6 more outperform votes than Carisma Therapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave NRx Pharmaceuticals an outperform vote while only 78.26% of users gave Carisma Therapeutics an outperform vote. CompanyUnderperformOutperformCarisma TherapeuticsOutperform Votes1878.26% Underperform Votes521.74% NRx PharmaceuticalsOutperform Votes24100.00% Underperform VotesNo Votes Which has preferable earnings and valuation, CARM or NRXP? NRx Pharmaceuticals has lower revenue, but higher earnings than Carisma Therapeutics. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.43-$86.88M-$1.56-0.13NRx PharmaceuticalsN/AN/A-$30.15M-$2.41-0.86 Does the media favor CARM or NRXP? In the previous week, NRx Pharmaceuticals had 4 more articles in the media than Carisma Therapeutics. MarketBeat recorded 6 mentions for NRx Pharmaceuticals and 2 mentions for Carisma Therapeutics. Carisma Therapeutics' average media sentiment score of 1.43 beat NRx Pharmaceuticals' score of 1.01 indicating that Carisma Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Carisma Therapeutics Positive NRx Pharmaceuticals Positive SummaryNRx Pharmaceuticals beats Carisma Therapeutics on 10 of the 17 factors compared between the two stocks. Get Carisma Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARM vs. The Competition Export to ExcelMetricCarisma TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.44M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.137.3222.5118.54Price / Sales0.43241.49397.62103.30Price / CashN/A65.8538.1834.62Price / Book0.316.486.734.25Net Income-$86.88M$143.41M$3.22B$248.18M7 Day Performance-10.66%2.58%1.38%1.03%1 Month Performance-9.14%5.00%2.79%2.70%1 Year Performance-87.38%-3.72%15.41%4.05% Carisma Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARMCarisma Therapeutics3.4396 of 5 stars$0.23+11.4%$1.93+755.6%-87.6%$9.24M$19.63M-0.1420Upcoming EarningsShort Interest ↓Positive NewsGap UpNRXPNRx Pharmaceuticals2.3526 of 5 stars$1.87-3.1%$28.25+1,410.7%-4.6%$31.63MN/A-0.872Analyst ForecastNews CoverageSRZNSurrozen3.9205 of 5 stars$9.60-1.5%$38.50+301.0%+7.0%$31.50M$10.66M-0.4480Short Interest ↓Positive NewsATHEAlterity Therapeutics1.9719 of 5 stars$3.45-1.4%$12.00+247.8%+55.0%$30.59MN/A0.0010Short Interest ↑News CoveragePositive NewsCVKDCadrenal Therapeutics3.2914 of 5 stars$16.18-3.4%$32.00+97.8%N/A$30.42MN/A-2.424Upcoming EarningsShort Interest ↓News CoveragePLURPluri0.593 of 5 stars$4.34+7.7%N/A-8.9%$30.37M$678,000.00-0.77150Upcoming EarningsHigh Trading VolumeMRNSMarinus Pharmaceuticals1.9497 of 5 stars$0.55-0.2%$4.79+771.6%-62.6%$30.32M$30.99M-0.22110Upcoming EarningsKZRKezar Life Sciences4.0372 of 5 stars$4.15-0.2%$39.50+851.8%-47.5%$30.32M$7M-0.3160Upcoming EarningsNews CoverageGap UpALXOALX Oncology2.5341 of 5 stars$0.57+2.9%$4.14+631.2%-97.0%$30.23MN/A-0.1940Upcoming EarningsESLAEstrella Immunopharma3.0462 of 5 stars$0.83+4.8%$16.00+1,823.1%+8.6%$30.09MN/A-3.20N/APositive NewsGap UpALLKAllakos4.6078 of 5 stars$0.33-0.3%$2.00+515.4%-71.1%$29.32MN/A-0.16190Upcoming EarningsShort Interest ↓Positive News Related Companies and Tools Related Companies NRx Pharmaceuticals Alternatives Surrozen Alternatives Alterity Therapeutics Alternatives Cadrenal Therapeutics Alternatives Pluri Alternatives Marinus Pharmaceuticals Alternatives Kezar Life Sciences Alternatives ALX Oncology Alternatives Estrella Immunopharma Alternatives Allakos Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CARM) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CARM Stock Free CARM Stock Alerts